Palliative Lung Radiotherapy: Higher Dose Leads to Improved Survival?

Area of Science:

• Oncology
• Radiotherapy
• Palliative Care

Background:

• Optimal palliative lung radiotherapy regimens are challenging to determine.
• Current guidelines recommend treatment stratification by performance status.
• Emerging evidence suggests higher radiotherapy doses may improve survival.

Purpose of the Study:

• To investigate the impact of fractionation regimen and other factors on survival in palliative lung cancer radiotherapy patients.
• To analyze the prognostic significance of patient characteristics and treatment prescriptions.
• To evaluate the association between radiotherapy dose and survival outcomes.

Main Methods:

• Retrospective analysis of 925 patients with non-small cell and small cell lung cancer.
• Univariable and multivariable survival analyses were performed.
• Investigated covariates included performance status, histology, smoking status, and fractionation scheme.

Main Results:

• Performance status, fractionation scheme, comorbidities, histology, smoking status, and gender were associated with survival in univariable analysis.
• Multivariable analysis identified better performance status and increased dose/fractionation (up to 30 Gy/10 fractions) as significant survival predictors.
• Mortality rates at 30 and 90 days were 9.2% and 34%, respectively.

Conclusions:

• Increased total radiotherapy dose (up to 30 Gy/10 fractions) was linked to better survival in palliative lung cancer patients.
• This association was observed regardless of patient performance status.
• Findings suggest optimizing radiotherapy dosage may enhance survival outcomes in palliative settings.